Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Isomorphic Labs adds Merck as an oncology partner after $5 billion raise

By Brian Buntz | November 19, 2026

Isomorphic Labs illustration of floating pink, peach and gold cubes against a peach-to-pink gradient

Credit: Isomorphic Labs

2026 is shaping up to be a pivotal year for Isomorphic Labs. In January, it signed Johnson & Johnson as its third pharma partner after Eli Lilly and Novartis, and CEO Demis Hassabis, Ph.D., moved the company’s first clinical trial target to the end of 2026. In May, the Alphabet spinoff raised a $2.1 billion Series B led by Thrive Capital. And now, two days after announcing a $5 billion Series C, the Alphabet-backed AI drug design company signed Merck as its latest partner, agreeing to use selected Merck datasets in its IsoDDE (Isomorphic Labs Drug Design Engine) to design small-molecule candidates against a single oncology target. Isomorphic unveiled IsoDDE in February as a unified computational drug-design system it says goes beyond AlphaFold 3, predicting how strongly a drug binds to its target as well as the structure of the complex.

Isomorphic began working with Lilly and Novartis in January 2024 to find small molecules for multiple targets. Novartis expanded its agreement in February 2025 to add up to three research programs. The Johnson & Johnson deal spans multiple targets and includes small molecules and biologics.

For the oncology project, Isomorphic will run predictions in IsoDDE and deliver molecular designs. By the company’s own benchmarking, IsoDDE more than doubles the accuracy of AlphaFold 3, the structure prediction model Isomorphic developed with Google DeepMind, on the hardest protein-ligand cases in the Runs N’ Poses benchmark.

Merck, which goes by MSD outside the U.S. and Canada, will handle preclinical and clinical development and will manufacture and market any resulting products. “The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions,” said George Addona, head of discovery, preclinical development and translational medicine at Merck Research Laboratories.

Isomorphic will receive an upfront payment and could earn milestone payments and tiered royalties on net sales. It can also co-fund development in exchange for higher royalties. In the top 20 drugmakers’ 2025 AI drug discovery deals, about 2% of $29.5 billion in headline value was paid up front, McKinsey found.

Isomorphic also plans to use the Series C to advance its internal programs and reported positive preclinical results in oncology and immunology. Isomorphic President Max Jaderberg called those programs “deep in pre-clinical development” on Nov. 2.


Filed Under: Drug Discovery, machine learning and AI, Oncology
Tagged With: AI drug design, AI drug discovery, Alphabet, AlphaFold 3, Demis Hassabis, Eli Lilly, George Addona, Google DeepMind, IsoDDE, Isomorphic Labs, Johnson & Johnson, Max Jaderberg, McKinsey, Merck, MSD, Novartis, oncology, small molecules
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at [email protected].

Related Articles Read More >

Recursion Pharmaceuticals Logo
Recursion’s Phase 3 FAP trial will count large-polyp removals as events under FDA-agreed design
Ball-and-stick model of the cancer drug imatinib
After six years in stealth, Humanitas bets on hybrid AI for drug discovery
NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE